Department of Endocrinology and Metabolism, The Second Affiliated Hospital of ZheJiang University School of Medicine, Hangzhou, Zhejiang, China.
Front Endocrinol (Lausanne). 2023 May 8;14:1101627. doi: 10.3389/fendo.2023.1101627. eCollection 2023.
Endocrine, metabolic, blood and immune disorders (EMBID) is a vital public health problem globally, but the study on its burden and global trends was scarce. We aimed to evaluate the global burden of disease and trends in EMBID from 1990 to 2019.
We extracted the data of EMBID-related on death cases, Age-standardized death rates (ASDRs), disability-adjusted life-years (DALYs), Age-standardized DALY rates, years of life lost (YLLs), Age-standardized YLL rates, years lived with disability (YLDs) and Age-standardized YLD rates between 1990 and 2019 from the Global Burden of Disease 2019, by sex, age, and year at the global and geographical region levels. The Annual rate of change was directly extracted from Global Health Data Exchange (GHDx) and we also calculated the age-related age-standardized rate (ASR) to quantify trends in EMBID-related deaths, DALYs, YLLs and YLDs.
Globally, the EMBID-related ASDRs showed an increasing trend, whereas the DALYs ASR, YLLs ASR and YLDs ASR were decreased between 1990 to 2019. Furthermore, High-income North America and Southern Sub-Saharan Africa had the highest both ASDRs and DALYs ASR, and Southern Sub-Saharan Africa and Caribbean had the highest both YLDs ASR and YLLs ASR in 2019. Males had a higher EMBID-related ASDRs than females, but the DALYs ASR in females were higher than males. The burden of EMBID was higher in older-aged compared to other age groups, especially in developed regions.
Although EMBID-related ASRs for DALYs-, YLLs- and YLDs declined at the global level from 1990 to 2019, but the ASDRs was increasing. This implied high healthcare costs and more burden of ASDRs due to EMBID in the future. Therefore, there was an urgent need to adopt geographic targets, age-specific targets, prevention strategies and treatments for EMBID to reduce negative health outcomes globally.
内分泌、代谢、血液和免疫系统疾病（EMBID）是一个全球性的重要公共卫生问题，但关于其负担和全球趋势的研究还很少。我们旨在评估 1990 年至 2019 年期间 EMBID 的全球疾病负担和趋势。
我们从全球疾病负担 2019 年中提取了 1990 年至 2019 年期间与 EMBID 相关的死亡病例、年龄标准化死亡率（ASDR）、残疾调整生命年（DALY）、年龄标准化 DALY 率、生命损失年（YLL）、年龄标准化 YLL 率、残疾生命年（YLD）和年龄标准化 YLD 率的数据，按性别、年龄和全球及地理区域水平进行划分。年变化率直接从全球卫生数据交换（GHDx）中提取，我们还计算了与年龄相关的年龄标准化率（ASR），以量化 EMBID 相关死亡、DALY、YLL 和 YLD 的趋势。
全球范围内，EMBID 相关的 ASDR 呈上升趋势，而 1990 年至 2019 年期间，DALY 的 ASR、YLL 的 ASR 和 YLD 的 ASR 呈下降趋势。此外，高收入的北美和撒哈拉以南非洲南部的 ASDR 和 DALY 的 ASR 最高，2019 年，撒哈拉以南非洲南部和加勒比地区的 YLD 的 ASR 和 YLL 的 ASR 最高。男性的 EMBID 相关 ASDR 高于女性，但女性的 DALY 的 ASR 高于男性。与其他年龄组相比，年龄较大的人群的 EMBID 负担更高，尤其是在发达地区。
尽管全球范围内 1990 年至 2019 年期间，与 DALY、YLL 和 YLD 相关的 EMBID 的 ASR 下降，但 ASDR 却在上升。这意味着未来由于 EMBID，医疗保健成本会更高，ASDR 的负担也会更重。因此，迫切需要针对地理目标、特定年龄的目标、预防策略和 EMBID 的治疗方法，以减少全球不良健康结果。
